✦ LIBER ✦

Relapse from a stage IV-S neuroblastoma and N-myc amplification

✍ Scribed by Bourhis, Jean; Hartmann, Olivier; Benard, Jean; Kalifa, Chantal; Riou, Guy

Book ID: 123362829
Publisher: Elsevier Science
Year: 1989
Weight: 248 KB
Volume: 25
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(89)90313-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

N-myc oncogene expression and amplificat

N-myc oncogene expression and amplification in metastatic lesions of stage IV-S neuroblastoma

✍ James Garvin Jr.; Israel Bendit; Perry D. Nisen 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 388 KB 👁 1 views

Amplification of N-myc oncogene in stage

Amplification of N-myc oncogene in stage II and IVS neuroblastomas may be a prognostic indicator

✍ Akira Nakagawara; Keiichi Ikeda; Tohru Tsuda; Ken Higashi; Takahiro Okabe 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 619 KB

Similar chromosomal patterns and lack of

✍ Hayashi, Yasuhide ;Inaba, Toshiya ;Hanada, Ryoji ;Yamada, Masao ;Nakagome, Yasuo 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 478 KB

N-myc oncogene and stage iv-s neuroblast

N-myc oncogene and stage iv-s neuroblastoma preliminary observations on ten cases

✍ Akira Nakagawara; Takehiko Sasazuki; Hiroshi Akiyama; Kiyoshi Kawakami; Akira Ku 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 705 KB

N-myc ONCOGENE AMPLIFICATION AND CATECHO

N-myc ONCOGENE AMPLIFICATION AND CATECHOLAMINE METABOLISM CHILDREN WITH NEUROBLASTOMA

✍ Nakagawara, A; Ikeda, K 📂 Article 📅 1987 🏛 The Lancet 🌐 English ⚖ 154 KB

Stratification of treatment of stage 4 n

Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status

✍ Kaneko, Michio; Nishihira, Hirokazu; Mugishima, Hideo; Ohnuma, Naomi; Nakada, Ko 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

Background. It has been shown that children aged more than 12 months with stage 3 and 4 neuroblastoma with N-myc amplification do worse than those without amplification. Development of an innovative chemotherapeutic protocol for patients in such an extremely poorrisk group was the purpose of this st